Web Exclusive
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.
Results 1 - 4 of 4